Study on How Endocrine Disruptors Affect Gut Microbiota and Their Role in Colorectal Cancer Development

What this Trial Is About

Colorectal cancer is a major health concern worldwide and was the second leading cause of cancer-related deaths in 2020. This research aims to study the relationship between colorectal cancer diagnosis, the activity and composition of the gut microbiota, and patients exposure to certain endocrine disruptors, specifically parabens and phthalates. These substances, commonly found in water and food, may affect gut microorganisms and potentially influence the development of colorectal cancer. This pilot study is conducted at a single center using a descriptive and comparative design involving two groups 100 patients diagnosed with colorectal cancer and 100 control patients without suspected colorectal cancer. Each participant will provide stool, hair, and urine samples, and complete a questionnaire about their exposure to endocrine disruptors. The inclusion period lasts 48 months, with each participant enrolled for up to one month. Routine care data will be collected for five years, making the total study duration about nine years. Participants will undergo sample collection and complete questionnaires to assess exposure to endocrine disruptors and analyze gut microbiota composition. Researchers will evaluate the association between fecal microbiota disruption and endocrine disruptor exposure, along with related microbiota and metabolome characteristics. The primary outcome is measured within one month per patient. Data on exposome, gut bacteria differences, and correlations with colorectal cancer will be gathered, with safety and follow-up continuing throughout the long-term study period.

Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)